ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for central nervous system disorders. Founded in 1993, ACADIA has made significant strides in the industry, particularly with its flagship product, Nuplazid, which is designed to treat Parkinson's disease psychosis. With a strong presence in North America and expanding operations in Europe, ACADIA is committed to addressing unmet medical needs through its unique approach to drug development. The company has garnered recognition for its dedication to research and has achieved notable milestones, including successful clinical trials and regulatory approvals. As a key player in the biopharmaceutical sector, ACADIA Pharmaceuticals continues to advance its mission of improving the lives of patients with serious neurological conditions.
DitchCarbon Score
How does ACADIA Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ACADIA Pharmaceuticals Inc.'s score of 3 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
ACADIA Pharmaceuticals Inc.'s reported carbon emissions
ACADIA Pharmaceuticals Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or evaluate their climate commitments. However, the pharmaceutical industry is increasingly focusing on sustainability and reducing greenhouse gas emissions. Companies are encouraged to adopt science-based targets and engage in initiatives that promote environmental responsibility. As of now, ACADIA's specific commitments or initiatives in this area remain unspecified.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ACADIA Pharmaceuticals Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
